6.22
0.32%
+0.02
After Hours:
6.41
0.19
+3.05%
Cytek BioSciences Inc stock is currently priced at $6.22, with a 24-hour trading volume of 732.83K.
It has seen a +0.32% increased in the last 24 hours and a -5.18% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $6.29 pivot point. If it approaches the $6.09 support level, significant changes may occur.
Previous Close:
$6.20
Open:
$6.41
24h Volume:
732.83K
Market Cap:
$812.53M
Revenue:
$193.01M
Net Income/Loss:
$-12.15M
P/E Ratio:
-155.50
EPS:
-0.04
Net Cash Flow:
$454.00K
1W Performance:
+7.99%
1M Performance:
-5.18%
6M Performance:
+41.69%
1Y Performance:
-47.64%
Cytek BioSciences Inc Stock (CTKB) Company Profile
Name
Cytek BioSciences Inc
Sector
Industry
Phone
877 922 9835
Address
46107 Landing Parkway, Fremont
Cytek BioSciences Inc Stock (CTKB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-19-23 | Initiated | Raymond James | Mkt Perform |
Jan-06-22 | Resumed | Piper Sandler | Overweight |
Cytek BioSciences Inc Stock (CTKB) Latest News
Cytek Biosciences, Inc. (CTKB) Stock Moves -0.33%: What You Should Know
Zacks Investment Research
Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
GlobeNewswire Inc.
Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
GlobeNewswire Inc.
Cytek Biosciences (CTKB) Is Considered a Good Investment by Brokers: Is That True?
Zacks Investment Research
Cytek Biosciences (CTKB) Loses -7.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research
Wall Street Analysts Believe Cytek Biosciences (CTKB) Could Rally 47.61%: Here's is How to Trade
Zacks Investment Research
Cytek BioSciences Inc Stock (CTKB) Financials Data
Cytek BioSciences Inc (CTKB) Revenue 2024
CTKB reported a revenue (TTM) of $193.01 million for the quarter ending December 31, 2023, a +17.67% rise year-over-year.
Cytek BioSciences Inc (CTKB) Net Income 2024
CTKB net income (TTM) was -$12.15 million for the quarter ending December 31, 2023, a -571.58% decrease year-over-year.
Cytek BioSciences Inc (CTKB) Cash Flow 2024
CTKB recorded a free cash flow (TTM) of $454.00 thousand for the quarter ending December 31, 2023, a +102.05% increase year-over-year.
Cytek BioSciences Inc (CTKB) Earnings per Share 2024
CTKB earnings per share (TTM) was -$0.09 for the quarter ending December 31, 2023, a -676.92% decline year-over-year.
About Cytek BioSciences Inc
Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. Its customers include pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. Cytek Biosciences, Inc. was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. The company was incorporated in 2014 and is headquartered in Fremont, California.
Cap:
|
Volume (24h):